596 Materials and Process Development for Hybrid Therapeutics

Wednesday, November 16, 2016: 3:15 PM - 5:45 PM
Continental 5 (Hilton San Francisco Union Square)
This session is focused on the recent advances and challenges in the discovery, development and manufacturing of antibody drug conjugates (ADCs) and other hybrid therapeutics. The topics to be discussed include advances in protein optimization and expression, conjugation, purification and formulation strategies, advances and challenges in the development of robust and scalable processes, implementation of Process Analytical Technologies (PAT) for process monitoring, and utilization of single-use technologies in manufacturing.

Pharmaceutical Discovery, Development and Manufacturing Forum
Pharmaceuticals (15B)

Selin Aytar
Email: selin.aytar@bms.com

Prince Bhebe
Email: pbhebe@amgen.com

3:15 PM
(596a) Site-Specific Conjugation of a Drug to an Antibody Via Nucleotide Binding Site
Nur Mustafaoglu, Franklin Mejia, Jonathan D. Ashley, Tanyel Kiziltepe and Basar Bilgicer

3:59 PM

4:21 PM
(596d) Process Development and Scale-up of an ADC Conjugation Process
Selin Aytar, Shawn Brueggemeier, Michael Hay, Annie Tam and Michael Smith

4:43 PM
(596e) In Situ crosslinked Endosomolytic Polymeric Vesicles for Immunotherapeutic Targeting of the Sting Pathway
Daniel Shae, Sema Sevimli, Alyssa Merkel, Denise Buenrostro, Anna Caldwell, Julie A. Sterling and John Wilson